INTRODUCTION: Thyroid eye disease is a debilitating, disfiguring, and 
potentially blinding periocular condition. Teprotumumab is a human insulin-like 
growth factor-I receptor monoclonal inhibitor antibody which indicated for 
treating thyroid eye disease.
AREAS COVERED: The authors performed a systematic review of the literature using 
the PubMed database, and the following keywords were used: 'teprotumumab,' 
'thyroid eye disease,' and 'insulin-like growth factor I receptor.' The chemical 
property, mechanism of action, pharmacokinetics, clinical efficacy, and safety 
of teprotumumab were introduced in this paper.
EXPERT OPINION: Teprotumumab is a human monoclonal antibody targeting 
insulin-like growth factor-I receptor. Clinical trials indicated that proptosis 
response of teprotumumab was 83%, and clinical activity score, diplopia, and 
quality of life were also better than placebo. Teprotumumab was well tolerated, 
common adverse reactions included muscle spasm, nausea, alopecia, diarrhea, 
fatigue, hyperglycemia, hearing impairment, dysgeusia, headache, and dry skin.